{"id":"W4417436058","doi":"10.1001/jamadermatol.2025.4950","title":"Vixarelimab in Patients With Prurigo Nodularis","year":2025,"lang":"en","type":"article","venue":"JAMA Dermatology","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"LEO Pharma; Galderma; Genentech; Kiniksa Pharmaceuticals; Regeneron Pharmaceuticals; Sanofi; Eli Lilly and Company; GlaxoSmithKline; Celldex Therapeutics; Amgen","keywords":"Prurigo nodularis; Placebo; Randomized controlled trial; Quality of life (healthcare); Clinical trial; Rating scale; Severity of illness","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002367965,0.0003486819,0.001114315,0.000191222,0.0003083636,0.0004672474,0.0002681963,0.0007040771,0.002771236],"category_scores_gemma":[0.002878605,0.0001942382,0.0006753532,0.000341883,0.0002270659,0.0003904551,0.000271293,0.0007627702,0.0004140013],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002233804,"about_ca_system_score_gemma":0.000593966,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003897485,"about_ca_topic_score_gemma":0.0008248409,"domain_scores_codex":[0.9989333,0.0006705825,0.0001073667,0.000110323,0.00009314304,0.00008527972],"domain_scores_gemma":[0.9988325,0.00043252,0.0003757641,0.00004041525,0.00006771844,0.0002510554],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.3549065,0.007940547,0.208248,0.006501429,0.002370338,0.001049578,0.0004642232,0.001179994,0.0119602,0.0004126758,0.008651728,0.3963147],"study_design_scores_gemma":[0.3060504,0.2735954,0.3765031,0.00134908,0.002713508,0.003606438,0.0003147219,0.002323551,0.002726184,0.0007615403,0.03000291,0.00005318601],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9332032,0.05643125,0.0006894654,0.002144102,0.0003706229,0.001446637,0.0005701113,0.0000691294,0.005075557],"genre_scores_gemma":[0.9918526,0.004462887,0.0007686914,0.000903641,0.000301597,0.000746064,0.0003010699,0.000003691189,0.00065967],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002771236,"threshold_uncertainty_score":0.01252311,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.002979455070905239,"score_gpt":0.2302415642247358,"score_spread":0.2272621091538306,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}